OR WAIT null SECS
Accurately targeted immunotherapies through reliable neoantigen recognition enable personalized medicine development.
Activation and expansion are essential for success in both autologous and allogeneic therapies.
Continuous manufacturing and a quality-by-design development approach are a natural fit.
December 18, 2023
Technical, regulatory, and personnel considerations characterize pharmaceutical compounding.
December 13, 2023
The new advisory committee will provide the agency with technical and scientific advice and recommendations on potential treatments for genetic metabolic diseases.
December 05, 2023
AstraZeneca will utilize Absci’s AI antibody drug creation platform to create an AI-designed antibody.
December 03, 2023
Matching excipients to API properties is essential.
Collaboration is a key component to achieving long-term success with genetic medicines.
November 30, 2023
Exagamglogene autotemcel seen as synechdoche.
November 29, 2023
Under this multi-year collaboration, Genentech and NVIDIA will use AI to optimize and accelerate each company’s platforms to discover and develop innovative therapeutics.
November 28, 2023
Webinar Date/Time: Thu, Dec 14, 2023 11:00 AM EST
November 23, 2023
In this episode of Drug Digest, Pharmaceutical Technology’s European/Senior Editor, Felicity Thomas, chats about the biggest trends impacting oral and topical drug delivery and how these trends are impacting the excipient sector with Nick DiFranco and Ashley Rezak from Lubrizol Life Science Health.
November 20, 2023
In part two of an interview with Thomas Langenickel, MD, chief medical officer at Ethris, Langenickel highlights the challenges in developing mRNA therapeutics for pulmonary diseases.